市场调查报告书

全球非酒精性脂肪性肝炎(NASH)治疗药及诊断市场:开发平台治疗药,诊断技术,治疗方法,各地区 - 成长,趋势,预测(2018年~2023年)

Hepatitis Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品编码 649745
出版日期 内容资讯 英文 120 Pages
商品交期: 2-3个工作天内
价格
全球非酒精性脂肪性肝炎(NASH)治疗药及诊断市场:开发平台治疗药,诊断技术,治疗方法,各地区 - 成长,趋势,预测(2018年~2023年) Hepatitis Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日内容资讯: 英文 120 Pages
简介

全球非酒精性脂肪性肝炎(NASH)治疗药及诊断市场在2018年到2023这段调查期间中,预测将以25.0%的年复合成长率成长。糖尿病及肥胖症的盛行率上升,研究开发的投资增加等,促进了该市场的成长。就各地区来看,新医疗技术的引进率高,高度优先于研究和开发活动的健全医疗保健基础设施使得美国兴起为最大市场。

本报告提供全球非酒精性脂肪性肝炎(NASH)市场调查,提供市场概要,各技术·用途·各地区的市场趋势,市场规模的变化与预测,成长要素·阻碍因素以及市场机会·课题分析,竞争情形,主要企业的简介等系统性资讯。

目录

第1章 简介

  • 市场定义

第2章 调查方法

第3章 摘要整理

第4章 主要影响要素

第5章 市场概要

  • 目前市场方案
  • 波特的五力分析
    • 买方议价能力
    • 供给企业谈判力
    • 新加入厂商业者的威胁
    • 替代品的威胁
    • 竞争企业间的敌对关系

第6章 市场动态

  • 成长要素
    • NASH疗法的利润管道
    • 全球性糖尿病和肥胖人口的患病率上升
    • 新型生物标志物技术的出现和肝活检技术的改进
  • 阻碍因素
    • 缺乏非酒精性脂肪肝病(NAFLD)的有效诊断
    • 治疗领域的技术进步停顿
  • 市场机会
  • 主要课题

第7章 非酒精性脂肪性肝炎(NASH)市场:各市场区隔

  • 开发平台治疗药物别
    • 第三阶段试验
      • 二乙酸(OCA)
      • Aramchol(花生酰胺胆鹼酸)
      • Saroglitazar
      • Elafibranor
      • 其他
  • 各诊断技术
    • 成像
    • 肝脏切片检查
    • 生物标记诊断
    • 其他
  • 各治疗法
    • 药物疗法
    • 胰岛素抗性改善治疗
    • 抗细胞因子治疗
    • 外科手术
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 中东·非洲
    • 南美

第8章 竞争情形

  • 合并·收购分析
  • 协定·联盟·合作
  • 新产品的上市

第9章 主要企业

  • AstraZeneca PLC
  • Conatus Pharmaceuticals, Inc.
  • Enzo Biochem, Inc.
  • Galmed Pharmaceuticals Ltd
  • Genfit Corp.
  • Gilead
  • Horizon Pharma PLC
  • Immuron
  • Intercept Pharmaceuticals, Inc.
  • Novo Nordisk A/S

第10章 市场未来展望

第11章 免责声明

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: 67936

The Hepatitis Therapeutics Market is expected to register a CAGR of 3.5% during the forecast period. Hepatitis is an inflammation, or swelling, of the liver. Hepatitis may occur due to drugs, alcohol use, or certain medical conditions. But in most of the cases, it is caused by a virus called viral hepatitis, and the most common forms are hepatitis A, B, and C. Hepatitis is a very common disease and can lead to serious scarring (cirrhosis) of the liver and liver failure, which can be fatal.

Some of the common symptoms of hepatitis are loss of appetite, nausea and vomiting, fatigue, fever, body aches, and stomach pain. Some people may experience light-colored bowel movements, dark urine, and yellowing of the skin or of the eyes (jaundice). Viral infections of the liver are classified as hepatitis A, B, C, D, and E. A different virus is responsible for each type of virally transmitted hepatitis. Hepatitis A is an acute, short-term disease, while hepatitis B, C, and D are mostly ongoing and chronic. Hepatitis E is usually acute but can be particularly dangerous in pregnant women. Hepatitis can be diagnosed through history and physical exam, liver function tests, blood tests, and ultrasound. Some of the complications of hepatitis B or C are chronic liver disease, cirrhosis, and liver cancer.

According to the World Health Organization (WHO), globally, 500 million people are estimated to be infected with hepatitis B or C. About 1.5 million people die in a year due to hepatitis infection, 1 in every 3 people get infected and most of the infected people do not know about it due to dormant symptoms. In addition, in European Hepatitis B and C affect millions of people. In addition, According to the European Centre for Disease Prevention and Control (ECDC), estimates an overall incidence of hepatitis B is 1.49 (Per 100,000), hepatitis c is 8.7 (Per 100,000) in the member states of the European Union (EU) and high prevalence in people who inject drugs.

An increase in the prevalence of viral hepatitis, promising pipeline of hepatitis drugs, and supportive government initiatives encouraging patients in the adoption of hepatitis drugs are the key driving factors in the hepatitis therapeutics market.

Key Market Trends

Hepatitis C Segment is Expected to Hold a Major Market Share in the Hepatitis Therapeutics Market

  • Hepatitis C is a liver infection which is caused by the hepatitis C virus. Hepatitis C can range from a mild to serious and lifelong illness. Acute hepatitis C occurs within the first 6 months after individual is exposed to the hepatitis C virus and chronic hepatitis C can be a lifelong infection with the hepatitis C virus if left untreated.
  • According to World Health Organization (WHO), hepatitis C virus (HCV) infection affects over 70 million people globally, and about 3.5 million Americans have hepatitis C virus (HCV) infection among them approximately 3.2 million have chronic (long-term) infection.
  • Hepatitis C segment holds a significant market share in the hepatitis therapeutics market and is anticipated to show a similar trend over the forecast period due to the high prevalence of hepatitis C in developing and developed regions and the growing availability of effective drug regimens in the market.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America expected to hold a major market share in the hepatitis therapeutics market due to an increase in the incidence of hepatitis, mortality due to hepatitis and increased spending on drugs for the treatment of hepatitis in this region. According to the Center for Disease Control (CDC), estimates about 2.4 million people are living with hepatitis C in the United States and approximately 850,000 people in this region estimated to be living with hepatitis B. In addition, 67% of persons infected with hepatitis B virus do not know they have the virus. Furthermore, favorable reimbursement policies, high adoption rates of advance therapeutics and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Hepatitis Therapeutics Market is fragmented competitive and consists of several major players. However, in terms of market share, few of the major players are currently dominating the market. Some of the leading market players include Merck & Co., Inc, Gilead Sciences, Inc, AbbVie Inc, Bristol Myers Squibb Company, F. Hoffmann-La Roche, Ltd, LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, NATCO Pharma Limited and Cipla, Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Viral Hepatitis
    • 4.2.2 Favorable Government Support for Creating Awareness about Hepatitis
    • 4.2.3 Increasing Availability of Technologically Advanced Therapeutic Products
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Issues
    • 4.3.2 Poor Reimbursement Policies
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Disease Type
    • 5.1.1 Hepatitis A
    • 5.1.2 Hepatitis B
    • 5.1.3 Hepatitis C
    • 5.1.4 Hepatitis D
    • 5.1.5 Other Types
  • 5.2 By Drug Class
    • 5.2.1 Interferon
    • 5.2.2 Monoclonal Antibody
    • 5.2.3 Non-structural protein 5A (NS5A) inhibitors
    • 5.2.4 Nucleotide Analog Reverse Transcriptase Inhibitors
    • 5.2.5 Nucleotide Analog NS5B Polymerase Inhibitors
    • 5.2.6 Multi Class Combination
    • 5.2.7 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East-and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Merck & Co., Inc
    • 6.1.2 Gilead Sciences, Inc
    • 6.1.3 AbbVie Inc
    • 6.1.4 Bristol Myers Squibb Company
    • 6.1.5 F. Hoffmann-La Roche, Ltd
    • 6.1.6 LAURUS Labs
    • 6.1.7 Zydus Cadila
    • 6.1.8 Hetero Healthcare Limited
    • 6.1.9 NATCO Pharma Limited
    • 6.1.10 Cipla, Inc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS